A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder

Objective: Major depressive disorder is often chronic, with relapse and recurrence common. Levomilnacipran extended-release is a potent and selective serotonin and reuptake inhibitor approved in the United States for treatment of major depressive disorder in adults. The objective of this study (NCT0...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shiovitz, Thomas, Greenberg, William M., Chen, Changzheng, Forero, Giovanna, Gommoll, Carl P.
Formato: Artigo
Lenguaje:Inglês
Publicado: Matrix Medical Communications 2014
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3960779/
https://ncbi.nlm.nih.gov/pubmed/24653937
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares